Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) r...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2011
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://ncbi.nlm.nih.gov/pubmed/21540861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.151
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires